AbbVie 8K Guidance Including the Impact of Acquired IPR&D and Milestones Expense | ABBV 3 Oct 24

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.


(in millions, except per share data)	Quarter Ended September 30, 2024						Full-Year Ended December 31, 2024
	Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range				Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range
			Low		High				Low		High
Previously announced guidance excluding Q3 2024 acquired IPR&D and milestones expense	$	—	$	2.92	$	2.96	$	1,101	$	10.71	$	10.91
Q3 2024 acquired IPR&D and milestones expense	82		(0.04)		(0.04)		82		(0.04)		(0.04)
Guidance including Q3 2024 acquired IPR&D and milestones expensea	$	82	$	2.88	$	2.92	$	1,183	$	10.67	$	10.87

AbbVie (ABBV) 8-KGuidance Including the Impact of Acquired IPR&D and Milestones Expense